JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide
JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s Ministry of Food and Drug...
Search results for "treatment"
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C (compound name: OLX72021), an...
Morning Stomach Burn? Understanding Gastritis and How to Protect Your Gut
"My stomach feels inflamed on an empty stomach in the morning." This common complaint often raises a critical question:...
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care
Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE.
High Timely Treatment Rate for Hemorrhagic Stroke Masks Capability Gap Among Hospitals
The Health Insurance Review & Assessment Service has added hemorrhagic stroke to its annual evaluation—which previously...
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival
Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...
Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy
CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical...
Prevention vs. Treatment: Why Cancer Therapy Demands a Completely Different Diet
What makes diabetes particularly dangerous is the risk of severe, systemic complications.
No Need to Travel to Seoul: How South Gyeongsang Valve Patients Access Local TAVI Treatment
For older adults, heart valve disease can be particularly difficult to detect. Symptoms often develop gradually,...
The Blood Cancer Decoy: Why Some Lymphoma Patients Stop Responding to Treatment
For patients diagnosed with aggressive blood cancers, receiving a proven targeted therapy offers a clear path toward a...